{"commentary":{"count":24,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":12,"podcast":9,"x_thread":2,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04895436\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ReVenG","nct_id":"NCT04895436","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=reveng-nct04895436. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"ReVenG","arms":[{"description":"Participants will receive venetoclax + obinutuzumab for six 28-day cycles followed by venetoclax for six 28-day cycles.","label":"Cohort 1 - venetoclax + obinutuzumab","type":"EXPERIMENTAL"},{"description":"Participants will receive venetoclax + obinutuzumab for six 28-day cycles followed by venetoclax for eighteen 28-day cycles.","label":"Cohort 2 - venetoclax + obinutuzumab","type":"EXPERIMENTAL"}],"collaborators":["F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer Institute"],"completion_date":{"date":"2029-01","type":"ESTIMATED"},"conditions":["Chronic Lymphocytic Leukemia (CLL)"],"enrollment":{"count":75,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Venetoclax","type":"DRUG"},{"name":"Obinutuzumab","type":"DRUG"}],"last_update":"2026-02-09","lead_sponsor":"AbbVie","official_title":"A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall response (OR) in Cohort 1 after end of combination treatment","timeFrame":"9 months"}],"references":[{"citation":"Castonguay M, Anderson MA, Thompson P, Seymour JF. Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective. Blood Adv. 2026 May 26;10(10):3357-3366. doi: 10.1182/bloodadvances.2026019871.","pmid":"41843779","type":"DERIVED"}],"start_date":{"date":"2022-03-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)","url":"https://clinicaltrials.gov/study/NCT04895436"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/reveng-nct04895436"}